STOCK TITAN
  1. Home
  2. News
  3. IGC

IGC Pharma Inc - IGC STOCK NEWS

IMPACT
SENTIMENT
IGC : NYSE
IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives
AI
IMPACT
SENTIMENT
IGC : NYSE
IGC Pharma Reports Second Quarter Fiscal 2024 Results
earnings
IMPACT
SENTIMENT
IGC : NYSE
IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy
IMPACT
SENTIMENT
IGC : NYSE
IGC Announces Results of its 2023 Annual Stockholders Meeting
IMPACT
SENTIMENT
IGC : NYSE
IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical Trials
earnings clinical trial
IMPACT
SENTIMENT
IGC : NYSE
IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico
clinical trial
IMPACT
SENTIMENT
IGC : NYSE
IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International Conference
IMPACT
SENTIMENT
IGC : NYSE
IGC Reports Financial Results for Fiscal Year Ended March 31, 2023
earnings
IMPACT
SENTIMENT
IGC : NYSE
IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research
IMPACT
SENTIMENT
IGC : NYSE
IGC Pharma Announces a $3 Million Private Placement of its Common Stock
Stock IGC logo
IGC Pharma Inc

NYSE:IGC

IGC Rankings

#6779 Ranked by Market Cap
#4055 Ranked by Stock Gains
N/A Ranked by Dividends

IGC Stock Data

Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Bethesda

About IGC

igc is developing a product portfolio of phytocannabinoid-based therapies through leading edge research for the treatment of a wide range of therapeutic indications. these include neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis, which are life altering or life threatening our mission is to treat pain, ptsd, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions with phytocannabinoid-based treatments